RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

First of Two Phase 3 NK Trials Expected to Start in November 2022 ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx” or “Company”), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is…

Click here to view original post